08:28 AM EDT, 03/19/2026 (MT Newswires) -- Taysha Gene Therapies ( TSHA ) reported 2025 net loss Thursday of $0.34 per diluted share, narrowing from a loss of $0.36 a year earlier.

Analysts polled by FactSet expected a loss of $0.37.

Revenue for the year ended Dec. 31 was $9.8 million, up from $8.3 million a year earlier.

Analysts surveyed by FactSet expected $5.9 million.

Shares of the company were up over 3% in Thursday premarket activity.